1. Home
  2. AKRO vs PI Comparison

AKRO vs PI Comparison

Compare AKRO & PI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • PI
  • Stock Information
  • Founded
  • AKRO 2017
  • PI 2000
  • Country
  • AKRO United States
  • PI United States
  • Employees
  • AKRO N/A
  • PI N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • PI Industrial Machinery/Components
  • Sector
  • AKRO Health Care
  • PI Technology
  • Exchange
  • AKRO Nasdaq
  • PI Nasdaq
  • Market Cap
  • AKRO 3.9B
  • PI 3.2B
  • IPO Year
  • AKRO 2019
  • PI 2016
  • Fundamental
  • Price
  • AKRO $50.56
  • PI $124.25
  • Analyst Decision
  • AKRO Strong Buy
  • PI Buy
  • Analyst Count
  • AKRO 6
  • PI 7
  • Target Price
  • AKRO $82.50
  • PI $136.00
  • AVG Volume (30 Days)
  • AKRO 1.1M
  • PI 418.2K
  • Earning Date
  • AKRO 08-08-2025
  • PI 07-30-2025
  • Dividend Yield
  • AKRO N/A
  • PI N/A
  • EPS Growth
  • AKRO N/A
  • PI N/A
  • EPS
  • AKRO N/A
  • PI N/A
  • Revenue
  • AKRO N/A
  • PI $363,539,000.00
  • Revenue This Year
  • AKRO N/A
  • PI N/A
  • Revenue Next Year
  • AKRO N/A
  • PI $25.60
  • P/E Ratio
  • AKRO N/A
  • PI N/A
  • Revenue Growth
  • AKRO N/A
  • PI 21.80
  • 52 Week Low
  • AKRO $21.34
  • PI $60.85
  • 52 Week High
  • AKRO $58.40
  • PI $239.88
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 44.48
  • PI 64.60
  • Support Level
  • AKRO $50.60
  • PI $107.42
  • Resistance Level
  • AKRO $52.55
  • PI $119.00
  • Average True Range (ATR)
  • AKRO 1.83
  • PI 5.33
  • MACD
  • AKRO -0.35
  • PI 0.62
  • Stochastic Oscillator
  • AKRO 17.66
  • PI 98.62

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About PI Impinj Inc.

Impinj Inc operates a platform that enables wireless connectivity to everyday items by delivering each item's identity, location, and authenticity to business and consumer applications. Its platform includes endpoint integrated circuits (ICs) product, a miniature radios-on-a-chip, which attach to and identify their host items; and connectivity layer that comprises readers, gateways, and reader ICs to wirelessly identify, locate, authenticate, and engage endpoints via RAIN, as well as provide power to and communicate bidirectionally with endpoint ICs. Geographically, the company has a business presence in the Americas, Asia Pacific, Europe, Middle East and Africa, of which key revenue is derived from the operations in the Asia Pacific region.

Share on Social Networks: